North America biosimilars market is expected to grow by 25.1% annually in the forecast period and reach $27.57 billion by 2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.
Highlighted with 29 tables and 54 figures, this 116-page report North America Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire North America biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
Market Structure
Growth Drivers
Restraints and Challenges
Emerging Product Trends & Market Opportunities
Porters Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.

Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
Recombinant Non-glycosylated Biosimilars
o Insulin
o Recombinant Human Growth Hormone (rHGH)
o Granulocyte Colony Stimulating Factor
o Interferon
Recombinant Glycosylated Biosimilars
o Monoclonal Antibodies (mAb)
o Erythropoietin (EPO)
o Follicle Stimulating Hormone
Recombinant Peptides and Others
o Tumor Necrosis Factor (TNF)-Inhibitor
o Parathyroid Hormone
o Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
Cancer
Autoimmune Disease
Blood Disorder
Diabetes
Growth Hormone Deficiency
Infectious Diseases
Other Indications

Based on Manufacturing, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
Contract Manufacturing
Inhouse Manufacturing

Based on End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
Hospitals and Clinics
Research Institutes
Other End Users

Geographically, the following national/local markets are fully investigated:
U.S.
Canada
Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddys Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)